Abstract
1. The disposition of a new β-blocking agent, chloropractolol, labelled with 14C and with 3H, has been studied in rats and mice.
2. After i.v. administration to the rat (25 mg/kg) of a mixture of [14C]- and [3H]chloropractolol, urinary and faecal excretion, biliary elimination and tissue distribution were similar for the two labelled species. However, 3% of the dose was recovered as 14CO2.
3. Chloropractolol and/or metabolites did not show high cardioselectivity. Uptake by heart of the two labelled species was very close to that found for [14C]practolol and [14C]propranolol.
4. Preliminary metabolic studies using h.p.l.c. have shown that in the rat chloropractolol is extensively metabolized, which contrasts with the more limited metabolism of practolol in the same species. Deacetylation is a minor route of metabolism. A structure for the main urinary metabolite is suggested.